Baptist Health South Florida
Trial Pipeline
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
NCT06991101
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
NCT06397560
Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
NCT05756985
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
NCT05681195
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
NCT06048094
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
NCT05789589
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
NCT05679674
ZYNRELEF for Pain Management in Total Knee Arthroplasty
NCT05644496
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
NCT05554302
Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease
NCT05534321
Cabozantinib for Patients With Recurrent or Progressive Meningioma
NCT05425004
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
NCT04689048
Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
NCT05504681
Dose-Escalated Spine SbRT for Localized Metastasis to the Spinal Column
NCT04802603
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
NCT01524211
Ablative Stereotactic MR-Guided Adaptive Reirradiation
NCT06397573
Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation
NCT04375891
Observational Trial of the Impact of Radiation Dose in Children With Brain and Skull Base Tumors.
NCT03972514
The Miami Heart Study at Baptist Health South Florida
NCT02508454
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
NCT04939246
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
NCT03274661
A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer
NCT02037542
A Web-based Approach to Treating Cardiovascular Disease Risk in Employees With Metabolic Syndrome
NCT01912209
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 63 |
| Phase 2 | 5 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for Baptist Health South Florida Shows
According to the ClinicalTrials.gov registry, Baptist Health South Florida is linked to 82 US clinical trials across every stage of research activity. Of those, 74 studies are currently recruiting — about 90% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 5% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Baptist Health South Florida reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 68 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Baptist Health South Florida is Brain Cancer with 5 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.